https://www.cgtlive.com/view/gilead-sciences-announces-119-billion-purchase-of-car-t-developer-kite-pharma
Gilead Sciences Announces $11.9 Billion Purchase of CAR-T Developer Kite Pharma | CGTlive®
Oct 13, 2026 - Gilead Sciences will acquire Kite Pharma by the end of 2017 in an $11.9 billion transaction that will place Gilead at the forefront of chimeric antigen...
gilead scienceskite pharmaannouncesbillionpurchase
https://www.kitepharma.com/privacy-policy/spanish-translations
Privacy Policy | Kite Pharma
Read the Privacy Policy to learn how Kite Pharma, Inc. (“Kite”) handles Personal Information received and processed by Kite.
privacy policykite pharma
https://www.ajmc.com/view/kite-pharmas-car-t-cell-treatment-approved-cheaper-than-tisagenlecleucel
Kite Pharma's CAR T-Cell Treatment Approved, Cheaper Than Tisagenlecleucel | AJMC
Oct 15, 2026 - Axicabtagene ciloleucel (Yescarta) has been approved to treat adult patients with diffuse large B-cell lymphoma who have not responded to or who have relapsed...
car t cellkite pharmatreatmentapprovedcheaper
https://www.pacbiztimes.com/2026/09/18/kite-pharma-relocating-to-thousand-oaks-2/
Kite Pharma relocating to Thousand Oaks | Pacific Coast Business Times
Sep 19, 2026 - The growing Conejo Valley biotech cluster has a new addition. Santa Monica-headquartered Kite Pharma is relocating its home office to two locations, one in...
kite pharmathousand oakspacific coastbusiness timesrelocating
https://www.cgtlive.com/view/kite-pharmas-car-t-cell-treatment-approved-cheaper-than-tisagenlecleucel
Kite Pharma's CAR T-Cell Treatment Approved, Cheaper Than Tisagenlecleucel | CGTlive®
Oct 7, 2026 - Axicabtagene ciloleucel (Yescarta) has been approved to treat adult patients with diffuse large B-cell lymphoma who have not responded to or who have relapsed...
car t cellkite pharmatreatmentapprovedcheaper
https://flcube.com/tag/kite-pharma/
Kite Pharma Archives - Insight, China's Pharmaceutical Industry
kite pharmapharmaceutical industryarchivesinsightchina